Skip to content

Study on curative effect and mechanism of Shenling Baizhu Powder in treating chronic rhinosinusitis with spleen deficiency and dampness

Study on curative effect and mechanism of Shenling Baizhu Powder in treating chronic rhinosinusitis with spleen deficiency and dampness

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095185
Enrollment
Unknown
Registered
2025-01-03
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Sinusitis

Interventions

Control Group:None
Operative control group:None

Sponsors

Hunan University of Traditional Chinese Medicine First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. It meets the diagnostic criteria of chronic sinusitis in the Chinese Guidelines for the Diagnosis and Treatment of Chronic Sinusitis (2018). 2. In line with the traditional Chinese medicine diagnosis of spleen deficiency and dampness syndrome; 3. Age between 18 and 55 years old; 4. Not using any other medication within 2 weeks; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. any condition that may prevent the subject from completing the clinical trial process, including but not limited to serious, difficult to control organic disease or infection, unstable angina pectoris, congestive heart failure, etc.; 2. severe abnormal liver and kidney function; Patients with symptomatic, uncontrollable neurological, mental diseases or mental disorders; Those who have cognitive impairment and speech deficits and are difficult to complete the questionnaire independently or with the assistance of others; 3. Pregnant, lactating women or those planning pregnancy; 4. people who are allergic or known to be allergic to the ingredients contained in the investigational drug; 5. Those who are participating in clinical trials within three months before the trial; 6. Patients with infectious diseases, such as hepatitis B, AIDS, syphilis, etc.; 7. Patients with tumors; 8. In addition to the above, the investigators judged that the patients were not suitable for participating in this clinical study.

Design outcomes

Primary

MeasureTime frame
Peripheral Blood Single-Cell Sequencing for Immune Markers;

Secondary

MeasureTime frame
TCM Syndrome Score (Spleen Qi Deficiency with Dampness Retention);Nasal Symptom Score (Nasal Obstruction, Discharge);

Countries

China

Contacts

Public ContactZhu Zhenhua

Hunan University of Traditional Chinese Medicine First Affiliated Hospital

zhenhua787@163.com+86 138 7315 0591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026